Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types

Standard therapy for acute myeloid leukemia (AML) consists of hematopoietic cell transplantation (HCT) including autologous-HCT (AUTO) and allogeneic-HCT from a matched-sibling donor (MSD) or well-matched unrelated donor (WM-URD). When a conventional donor is not available, HCT from a partially-matc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jae-Ho, Kim, Hee-Je, Park, Sung-Soo, Jeon, Young-Woo, Lee, Sung-Eun, Cho, Byung-Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong-Wook, Min, Woo-Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522252/
https://www.ncbi.nlm.nih.gov/pubmed/28206975
http://dx.doi.org/10.18632/oncotarget.15295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522252/
https://www.ncbi.nlm.nih.gov/pubmed/28206975
http://dx.doi.org/10.18632/oncotarget.15295

Ejemplares similares